LEADER 06634nam 22007695 450 001 9910568262803321 005 20260202154322.0 010 $a3-030-95334-3 024 7 $a10.1007/978-3-030-95334-8 035 $a(MiAaPQ)EBC6963477 035 $a(Au-PeEL)EBL6963477 035 $a(CKB)21672596700041 035 $a(PPN)262170140 035 $a(OCoLC)1354205823 035 $a(DE-He213)978-3-030-95334-8 035 $a(EXLCZ)9921672596700041 100 $a20220426d2022 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNovel Synthetic Drugs in Migraine /$fedited by Paolo Martelletti, Lars Edvinsson 205 $a1st ed. 2022. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2022. 215 $a1 online resource (114 pages) 225 1 $aHeadache,$x2197-6538 311 08$aPrint version: Martelletti, Paolo Novel Synthetic Drugs in Migraine Cham : Springer International Publishing AG,c2022 9783030953331 320 $aIncludes bibliographical references. 327 $aIntro -- Foreword -- Preface -- Contents -- Chapter 1: Novel Pharmacological Targets of Migraine: An Overview -- 1.1 Introduction -- 1.2 Novel Pharmacological Treatments for Migraine -- 1.3 Acute Treatment for Migraine Beyond Ergots and Triptans -- 1.3.1 5-HT1F Agonists: Ditans -- 1.3.2 CGRP Receptor Antagonists: Gepants -- 1.4 Gepants as Prophylactic Treatment for Migraine -- 1.5 Mechanisms of Action of Ditans and Gepants: Is It a Common Pathway? -- 1.6 Conclusion -- References -- Chapter 2: Molecular and Cellular Mechanisms of CGRP Antagonists -- 2.1 Introduction -- 2.1.1 Trigeminovascular System -- 2.2 Neuropeptide Signaling -- 2.2.1 CGRP -- 2.2.2 Amylin -- 2.2.3 Neuropeptide Receptors -- 2.2.4 Downstream Activation -- 2.3 The Blood-Brain Barrier -- 2.4 CGRP Antagonists -- 2.5 Molecular Targets -- 2.6 Cellular Targets -- 2.6.1 Vascular Targets -- 2.6.2 Trigeminal Targets -- 2.6.2.1 Satellite Glial Cells -- 2.6.2.2 Neuronal Targets -- 2.6.2.3 Potential Antagonistic Effect at the Nodes of Ranvier -- 2.7 Non-migraine Targets -- 2.8 Conclusion -- References -- Chapter 3: Atogepant -- 3.1 Introduction -- 3.2 Chemical Characteristics, Pharmacodynamics and Pharmacokinetics -- 3.3 Atogepant in Preclinical Studies -- 3.4 Efficacy of Atogepant in Phase II and Phase III Clinical Trials -- 3.5 Safety and Adverse Events -- 3.6 Future Developments -- 3.7 Conclusions -- References -- Chapter 4: Ubrogepant -- 4.1 Introduction -- 4.2 Pharmacology -- 4.2.1 Chemistry -- 4.2.2 Pharmacodynamics -- 4.2.3 Pharmacokinetics and Metabolism -- 4.3 Clinical Registered Trials -- 4.3.1 Phase I Trials -- 4.3.2 Phase II Trials -- 4.3.3 Phase III Trials: ACHIEVE I and II and Their Extension Study -- 4.3.4 Post-marketing Studies -- 4.4 Safety and Tolerability -- 4.5 Regulatory Affairs and Clinical Approval -- 4.6 Conclusions -- References -- Chapter 5: Rimegepant. 327 $a5.1 Introduction -- 5.2 Introduction to the Compound -- 5.2.1 Chemistry -- 5.2.2 Pharmacodynamics -- 5.2.3 Pharmacokinetics and Metabolism -- 5.2.4 Metabolism -- 5.2.5 Drug Interactions -- 5.3 Clinical Efficacy -- 5.3.1 Phase II Studies -- 5.3.2 Phase III Studies -- 5.4 Safety and Tolerability -- 5.4.1 Phase I Studies -- 5.4.2 Phase II Studies -- 5.4.3 Phase III Studies -- 5.5 Exclusion Criteria -- 5.6 Conclusions -- References -- Chapter 6: Zavegepant -- 6.1 Introduction -- 6.2 Preclinical Pharmacology -- 6.3 Clinical Trials -- 6.3.1 Safety and Tolerability -- 6.3.2 Efficacy -- 6.4 Conclusion -- References -- Chapter 7: Molecular Mechanisms of 5-HT1F Receptor Agonists -- 7.1 Serotonin (5-HT) and 5-HT Receptors -- 7.2 5-HT1B/D and 5-HT1F Receptors and Migraine Treatment -- References -- Chapter 8: Lasmiditan -- 8.1 Introduction -- 8.2 Pharmacological Profile -- 8.3 Preclinical Studies -- 8.4 Clinical Studies -- 8.5 Safety -- 8.6 Drug Interactions -- 8.7 Conclusion -- References -- Chapter 9: Update on Old and Current Targets for Antimigraine Therapies -- 9.1 Introduction -- 9.2 Current Drugs for Acute Migraine -- 9.2.1 NSAIDs and Other Analgesics -- 9.2.2 5-Hydroxytryptamine Receptors in Migraine -- 9.2.3 Neurokinin Receptors and Blockers -- 9.2.4 Gepants -- 9.3 Targets for Prophylaxis of Migraine -- 9.3.1 Beta-Adrenoceptor Blockers -- 9.3.2 Angiotensin II AT1 Receptor Antagonists -- 9.3.3 Anticonvulsant Drugs -- 9.3.4 Tricyclic Antidepressant -- 9.3.5 Calcium Channel Antagonists -- 9.3.6 Onabotulinum Toxin A -- 9.4 Conclusion -- References. 330 $aPublished in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development. 410 0$aHeadache,$x2197-6538 606 $aInternal medicine 606 $aNeurology 606 $aEmergency medicine 606 $aPain medicine 606 $aPharmacology 606 $aInternal Medicine 606 $aNeurology 606 $aEmergency Medicine 606 $aPain Medicine 606 $aPharmacology 606 $aMigranya$2thub 608 $aLlibres electrňnics$2thub 615 0$aInternal medicine. 615 0$aNeurology. 615 0$aEmergency medicine. 615 0$aPain medicine. 615 0$aPharmacology. 615 14$aInternal Medicine. 615 24$aNeurology. 615 24$aEmergency Medicine. 615 24$aPain Medicine. 615 24$aPharmacology. 615 7$aMigranya 676 $a615.1 676 $a616.84912061 702 $aMartelletti$b Paolo 702 $aEdvinsson$b Lars 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910568262803321 996 $aNovel synthetic drugs in migraine$92966507 997 $aUNINA